PHARMANJE
Turnover is estimated at about €600,000, probably between €360,000 and €1.0m. The abbreviated format does not state turnover.
Balance sheet
balance sheet total €521,608 on 30-09-2015in euro
in euro
Staff
€42,233
Staff costs divided by the average number of full-time equivalents.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|
| 165,689 | 146,986 | 137,101 | 124,576 | 88,967 | 158,833 | ||
| 126,757 | 115,786 | 116,349 | 116,039 | 75,354 | 134,932 | ||
| 371 | 518 | 24,242 | 7,076 | 6,094 | 783,733 | ||
| -11,475 | -2,351 | 34,169 | -33,558 | -17,674 | - | ||
| -100,152 | -224,114 | -338,642 | -434,768 | -540,807 | -595,749 | ||
| 33.5% | 17.6% | 7.6% | 2.9% | -1.7% | -0.5% | ||
| 0.70 | 0.52 | 0.42 | 0.34 | 0.31 | 0.30 | ||
| 0.36 | 0.29 | 0.23 | 0.15 | 0.17 | 0.19 | ||
| 1.99 | 4.69 | 12.24 | 33.06 | - | - | ||
| 41.5% | 51.9% | 59.0% | 164.3% | - | - | ||
| 13.9% | 9.1% | 4.5% | 4.8% | -1.2% | -3.3% |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||
20/58 |
521,608 | 580,906 | 650,307 | 686,070 | 784,153 | 870,416 | |
21/28 |
283,951 | 337,835 | 400,180 | 463,315 | 541,583 | 619,872 | |
21 |
139,979 | 183,050 | 226,120 | 269,191 | 312,261 | 355,331 | |
22/27 |
143,972 | 154,785 | 174,060 | 194,124 | 229,322 | 264,540 | |
22 |
132,627 | 137,184 | 142,034 | 147,198 | 152,694 | 158,545 | |
23 |
173 | 601 | 949 | 2,017 | 2,221 | 1,995 | |
24 |
11,172 | 17,000 | 31,076 | 44,910 | 74,407 | 104,000 | |
29/58 |
237,657 | 243,072 | 250,128 | 222,755 | 242,570 | 250,544 | |
3 |
117,076 | 107,580 | 114,611 | 124,436 | 106,064 | 85,591 | |
30/36 |
117,076 | 107,580 | 114,611 | 124,436 | 106,064 | 85,591 | |
40/41 |
58,109 | 56,726 | 53,991 | 56,134 | 54,599 | 70,995 | |
40 |
58,109 | 56,575 | 53,374 | 54,297 | 54,568 | 69,828 | |
41 |
- | 151 | 616 | 1,837 | 31 | 1,167 | |
54/58 |
61,332 | 72,807 | 75,158 | 40,989 | 74,547 | 92,221 | |
490/1 |
1,141 | 5,958 | 6,368 | 1,197 | 7,360 | 1,737 | |
| Balance sheet: equity and liabilities | |||||||
10/49 |
521,608 | 580,906 | 650,307 | 686,070 | 784,153 | 870,416 | |
10/15 |
174,541 | 102,039 | 49,117 | 20,145 | -12,957 | -3,929 | |
10/11 |
25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | |
100 |
25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | |
13 |
149,541 | 77,039 | 24,117 | - | - | - | |
130 |
2,500 | 2,500 | 2,500 | - | - | - | |
133 |
147,041 | 74,539 | 21,617 | - | - | - | |
14 |
- | - | - | -4,855 | -37,957 | -28,929 | |
17/49 |
347,067 | 478,867 | 601,191 | 665,925 | 797,110 | 874,345 | |
42/48 |
337,810 | 467,186 | 588,770 | 657,523 | 783,376 | 846,294 | |
42 |
- | 75,000 | 150,000 | 225,000 | - | - | |
43 |
- | - | - | - | 300,000 | 375,000 | |
430/8 |
- | - | - | - | 300,000 | 375,000 | |
44 |
149,193 | 137,518 | 149,411 | 147,734 | 205,511 | 179,034 | |
440/4 |
149,193 | 137,518 | 149,411 | 147,734 | 205,511 | 179,034 | |
45 |
19,373 | 12,609 | 13,125 | 7,757 | 9,530 | 47,389 | |
450/3 |
7,196 | 400 | 827 | 172 | 1,232 | 18,907 | |
454/9 |
12,178 | 12,209 | 12,299 | 7,585 | 8,298 | 28,481 | |
47/48 |
169,244 | 242,059 | 276,234 | 277,032 | 268,335 | 244,871 | |
492/3 |
9,257 | 11,681 | 12,421 | 8,402 | 13,734 | 28,051 | |
| Income statement | |||||||
76A |
- | - | - | 1,593 | - | - | |
9900 |
253,160 | 234,196 | 220,957 | 196,347 | 170,392 | 296,807 | |
62 |
84,465 | 84,696 | 80,613 | 69,497 | 79,437 | 134,320 | |
630 |
54,255 | 62,863 | 87,377 | 82,937 | 84,382 | 163,861 | |
640/8 |
3,006 | 2,514 | 3,243 | 2,274 | 1,988 | 3,655 | |
9901 |
111,433 | 84,124 | 49,724 | 41,640 | 4,585 | -5,028 | |
75/76B |
3,455 | 4,011 | 4,121 | 1,632 | 4,084 | 11,242 | |
75 |
3,455 | 4,011 | 4,121 | 1,632 | 4,084 | 11,242 | |
65/66B |
9,468 | 12,340 | 13,353 | 11,712 | 17,698 | 35,143 | |
65 |
9,468 | 12,340 | 13,353 | 11,712 | 17,698 | 35,143 | |
9903 |
105,420 | 75,795 | 40,492 | 33,152 | -9,028 | -28,929 | |
67/77 |
32,918 | 22,872 | 11,520 | 51 | - | - | |
9904 |
72,502 | 52,923 | 28,972 | 33,102 | -9,028 | -28,929 | |
9905 |
72,502 | 52,923 | 28,972 | 33,102 | -9,028 | -28,929 | |
| Appropriation of the result | |||||||
9906 |
72,502 | 52,923 | 24,117 | -4,855 | -37,957 | -28,929 | |
691/2 |
72,502 | 52,923 | 24,117 | - | - | - | |
6920 |
- | - | 2,500 | - | - | - | |
6921 |
72,502 | 52,923 | 21,617 | - | - | - | |
| Social balance sheet | |||||||
9087 |
2 | 2 | 2 | 1.8 | 2 | 2 | |
Hours worked1013 |
3,496 | 3,528 | 4,492 | 3,183 | 3,586 | 5,933 | |
| Document | |||||||
Source: Annual accounts 2015 (PDF), filed on 29-03-2016.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-09-2015 | abbreviated format | 29-03-2016 | 2016-07200515 | |
| 30-09-2014 | abbreviated format | 30-03-2015 | 2015-07600060 | |
| 30-09-2013 | abbreviated format | 03-04-2014 | 2014-08200497 | |
| 30-09-2012 | abbreviated format | 30-04-2013 | 2013-11100112 | |
| 30-09-2011 | abbreviated format | 02-04-2012 | 2012-07600014 | |
| 30-09-2010 | abbreviated format | 01-04-2011 | 2011-07800350 |
Insights on PHARMANJE
The operating result for 2015 is 32% higher than in 2014 and the highest since 2010. It is the fifth rise in a row.
Debt's share of the balance-sheet total falls from 82.4% to 66.5%. Equity is higher and debt is lower.